To explore whether atorvastatin can improve the clinical prognosis of patients with intracranial hematoma treated by stereotactic minimally invasive technique. Methods: In this study, we included 98 patients that met our requirements and were diagnosed with spontaneous intracerebral hemorrhage. Patients were randomly divided into the minimally invasive surgery group (75 cases) and combined treatment group (23 cases). Patients in both groups were given minimally invasive surgery and conventional medication, and the combined treatment group was additionally given atorvastatin calcium tablets 20 mg starting within 24 h of admission for 90 days at a dose of 20 mg/d. Patients were followed for 90 days. The primary endpoint of follow-up was the proportion of patients with adverse outcomes at 90 d as indicated by a >3 Modified Rankin Scale (mRS) score. The secondary endpoint was the hematoma volume change in the computed tomography (CT) of the skull. Results: At 1 and 2 weeks after treatment and at patient discharge, the two groups showed no significant difference in hematoma volume (P>0.05). By the end of the 90-day follow-up, the proportion of patients with adverse outcomes in the minimally invasive surgery group was significantly higher than that in the combined treatment group (P<0.01). The two groups showed no significant difference in rates of complication (P>0.05). Conclusion: For patients who have elected for stereotactic minimally invasive techniques to remove intracranial hematomas, combined treatment with atorvastatin can improve the clinical prognosis at 90-day.